BioCryst: Difference between revisions

From Bhamwiki
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:BioCryst logo.png|right|225px]]
[[Image:BioCryst logo.png|right|225px]]
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical research company founded in [[1986]] in [[Birmingham]] as a spin-off of [[UAB]] research. It went public in [[1994]] and is currently headquartered in Raleigh, North Carolina, with research operations at its "Discovery Research Center and Laboratory Center of Excellence" in Birmingham.
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) was a pharmaceutical research company founded in [[1986]] in [[Birmingham]] as a spin-off of [[UAB]] research. It went public in [[1994]] and moved its headquarters to Raleigh, North Carolina in [[2010]]. It maintains a "Discovery Research Center and Laboratory Center of Excellence" in Birmingham.


Formerly headquartered at 2190 [[Parkway Lake Drive]], BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
Formerly headquartered at 2190 [[Parkway Lake Drive]], BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.


The current CEO is [[Jon Stonehouse]], who succeeded co-founder [[Charles E. Bugg]] after his retirement in [[2007]].
BioCryst merged with Idera Pharmaceuticals of Exton, Pennsylvania in [[2018]].
 
==Chief executives==
* [[Charles Bugg]], 1986-2007
* [[Jon Stonehouse]], 2007-2018
* Vincent Milano, 2018-


==Products==
==Products==
BioCryst is developing the following drug treatments:
BioCryst has developed several drug treatments:
* Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
* Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
* Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
* Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
Line 18: Line 23:
==References==
==References==
* BioCryst Pharmaceuticals, Inc. (2005) ''[http://www.biocryst.com/pdf/biocryst_2005_ar.pdf Corporate Report 2005]'' (PDF) - accessed September 21, 2006
* BioCryst Pharmaceuticals, Inc. (2005) ''[http://www.biocryst.com/pdf/biocryst_2005_ar.pdf Corporate Report 2005]'' (PDF) - accessed September 21, 2006
* [http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f16%2f0001206774-05-000364.html#FIS_BUSINESS BioCryst Pharmaceuticals Inc.] corporate spotlight at NASDAQ. - Accessed September 21, 2006
* [http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f16%2f0001206774-05-000364.html#FIS_BUSINESS BioCryst Pharmaceuticals Inc.] corporate spotlight at NASDAQ. - accessed September 21, 2006
* Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." ''Birmingham News''
* Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." {{BN}}
* DeButts, Jimmy (November 13, 2009) "BioCryst sees healthy future after flu drug." ''Birmingham Business Journal''
* DeButts, Jimmy (November 13, 2009) "BioCryst sees healthy future after flu drug." {{BBJ}}
* Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." ''Birmingham Business Journal''
* Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." {{BBJ}}
* Patchen, Tyler (January 23, 2018) "BioCryst Pharmaceuticals to merge with Pennsylvania pharmaceutical company." {{BBJ}}


==External links==
==External links==

Revision as of 17:09, 23 January 2018

BioCryst logo.png

BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) was a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research. It went public in 1994 and moved its headquarters to Raleigh, North Carolina in 2010. It maintains a "Discovery Research Center and Laboratory Center of Excellence" in Birmingham.

Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.

BioCryst merged with Idera Pharmaceuticals of Exton, Pennsylvania in 2018.

Chief executives

Products

BioCryst has developed several drug treatments:

  • Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
  • Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
  • Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
  • Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
  • BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
  • Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
  • BCX-4208 Oral, for treatment of Hepatitis C

References

External links

Retrieved from "http://bhamwiki.com/w/index.php?title=BioCryst&oldid=144867"